One billion retail oral antithrombotic drugs "emergency"!

News from the medical network on August 23.
The official website of the State Food and Drug Administration showed that Shaanxi Buchang High-tech Pharmaceutical was approved for its imitation of 4 types of rivaroxaban tablets.
Thrombotic drugs; In addition, Suzhou Dawnrays Pharmaceuticals and Lepu Pharmaceuticals' rivaroxaban tablets submitted their marketing applications in generic 4 categories and were accepted by the CDE
.
According to data from Mi Nei, in 2020, the sales volume of terminal antithrombotic drugs in urban physical pharmacies in China will exceed 3 billion yuan
.
From the perspective of TOP10 manufacturers, Bayer's market share surpassed Sanofi to win the "first brother" throne
.
Among the TOP10 products, the market size of clopidogrel bisulfate tablets has fallen sharply; from the perspective of growth rate, apixaban tablets are the fastest, with a growth rate of more than 500% "breaking" into the top ten
.
Since the beginning of this year, 9 oral antithrombotic drugs have been reported for production and are under review and approval.
4 products including clopidogrel bisulfate aspirin tablets and selepag tablets have not been approved for generic drugs.
Jiangsu Hausen Pharmaceutical Group, Yangtze River Pharmaceutical Group, Guangzhou Hairui Pharmaceutical, Hainan Simcere Pharmaceutical, and other companies are under review and approval
.

The antithrombotic drug market is making waves again! Bayer wins the "one brother" throne
.
Sales of terminal antithrombotic drugs in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan) Source: Meinenet.
com.
The pharmaceutical company was approved for the generic 4 types of rivaroxaban tablets, which were deemed to have been reviewed and became the company's first approved antithrombotic drug; in addition, rivaroxaban from Suzhou Dawnrays Pharmaceuticals and Lepu Pharmaceuticals The film was accepted by CDE after submitting its application for listing in 4 types of imitations.
.
.
The antithrombotic drug market has made waves again
.
According to data from Meinnet.
com, the terminal antithrombotic drug market in China's urban physical pharmacies has maintained steady growth in recent years.
In 2018, it exceeded 3 billion yuan.
In 2019, it reached a new high.
In 2020, it declined slightly.
This is the first time that there has been a negative growth in the past five years.

.
From the perspective of dosage form, the market share of oral-related dosage forms accounted for more than 95%
.
From the perspective of TOP10 manufacturers, Bayer's market share surpassed Sanofi to take the "one brother" throne.
Shenzhen Xinlitai Pharmaceutical Co.
, Ltd.
ranks third.
In addition, domestic pharmaceutical companies include CSPC Ouyi Pharmaceutical Co.
, Ltd.
and Lepu Pharmaceutical Co.
, Ltd.
5 companies including Pharmaceutical and Beijing Tide Pharmaceutical
.
Oral antithrombotic drugs approved for marketing since 2021 Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Since this year, a total of 6 oral antithrombotic drugs have been approved for marketing.
Among them, the number of approved companies for rivaroxaban tablets The most, nearly 20, followed by more than 10 ticagrelor tablets
.
In addition, Tianjin Hongri Pharmaceutical won the "first imitation + first review" of sargrelide hydrochloride tablets, which is one of the representative drugs of selective serotonin receptor inhibitors.
The manufacturer only has the original research Tianjin Tanabe Pharmaceutical
.

　　One billion retail oral antithrombotic drugs "emergency", soaring 500% of the varieties reached the TOP10 in
2020 China's urban physical pharmacies terminal antithrombotic chemical products TOP10 (unit: 100 million yuan) Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern Note: Sales of less than 100 million yuan are shown with "*".
From the perspective of product TOP10, the total market share of clopidogrel bisulfate tablets, aspirin enteric-coated tablets, and rivaroxaban tablets accounted for more than 70%, and the market concentration was high.

.
Among them, clopidogrel bisulfate tablets have been the leading product in the antithrombotic drug market for many years, and it is also the only product with sales of more than 1 billion yuan
.
In terms of growth rate, apixaban tablets are the fastest, with a growth rate of more than 500% "breaking into" the product TOP10; rivaroxaban tablets, ticagrelor tablets, and sulodexide soft capsules all have more than 20%
.
Sales of Clopidogrel Hydrogen Sulfate Tablets in Chinese Urban Entity Pharmacies in Recent Years (Unit: 100 million yuan) Source: Mynet.
com China’s urban entity pharmacies terminal competition pattern Clopidogrel Hydrogen Sulfate Tablets won the exclusive bid for the 4+7 collection of CITIC Litai, 4 +7 Three companies including Sanofi, CSPC Ouyi Pharmaceutical and Lepu Pharmaceutical won the bids
.
According to data from Menet.
com , the peak sales of clopidogrel bisulfate tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) peaked in 2018, exceeding 12 billion yuan in 2019.
There was a slight year-on-year decline, and in 2020, the year-on-year decline was nearly 60%
.
The peak sales of physical pharmacies in Chinese cities occurred in 2019, exceeding 1.
6 billion yuan, and a year-on-year decline of 33.
69% in 2020
.
There are more than 15 manufacturers of this product, of which Sanofi has the largest market share
.
It is worth noting that among the TOP10 products, apixaban tablets and ticagrelor tablets are the third batch of collectively collected varieties, and rivaroxaban tablets and dabigatran etexilate capsules are the fifth batch of collectively collected varieties.
It remains to be seen whether the variety can continue the growth trend
.
As centralized procurement enters the normalization stage, the number of included varieties will increase.
For retail pharmacies, the national policy encourages them to participate in centralized procurement.
In the future, the impact on retail pharmacies may gradually appear, and the industry structure will accelerate reshuffle
.

　　Pharmaceutical companies "get together" 3 major products, Hausen, Yangtze River.
.
.
the first to imitate
the oral antithrombotic drugs that have been submitted for production since 2021.
The antithrombotic drug is reported for production and is under review and approval
.
In terms of the number of companies, the largest number of companies reporting rivaroxaban tablets, including Suzhou Dawnrays Pharmaceuticals, Lepu Pharmaceuticals, Hunan Hengsheng Pharmaceuticals, etc.
; followed by apixaban tablets and dabigatran etexilate capsules.
There are 4 each
.
4 products of clopidogrel bisulfate aspirin tablets, selepagram tablets, ticagrelor dispersible tablets, and idoxaban tosylate tablets have not been approved for generic drugs, Jiangsu Hausen Pharmaceutical Group, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, Hainan Simcere Pharmaceuticals and many other companies are under review and approval
.

　　Source: State Drug Administration official website, Mi Nei.
com database, etc.
If there are any errors or omissions, please correct me
.